Zsuzsanna Bordan, Robert Batori, Stephen Haigh, Xueyi Li, Mary Louise Meadows, Zach L Brown, Madison A West, Kunzhe Dong, Weihong Han, Yunchao Su, Qian Ma, Yuqing Huo, Jiliang Zhou, Mahmoud Abdelbary, Jennifer Sullivan, Neal L Weintraub, David W Stepp, Feng Chen, Scott A Barman, David J R Fulton
BACKGROUND: Pulmonary arterial hypertension (PAH) is high blood pressure in the lungs that originates from structural changes in small resistance arteries. A defining feature of PAH is the inappropriate remodeling of pulmonary arteries (PA) leading to right ventricle failure and death. Although treatment of PAH has improved, the long-term prognosis for patients remains poor, and more effective targets are needed. METHODS: Gene expression was analyzed by microarray, RNA sequencing, quantitative polymerase chain reaction, Western blotting, and immunostaining of lung and isolated PA in multiple mouse and rat models of pulmonary hypertension (PH) and human PAH...
April 29, 2024: Circulation